Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 8/20 | 0.41 |
| ▸ | CD44 | P16070 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL107311 | 0.88 | PNMT (0.54) | PNMTCD44MAOBDRD2DRD3 | |
| SCHEMBL1639710 | 0.85 | HTR2C (0.45) | PNMTCD44MAOBDRD2DRD3 | |
| SCHEMBL104955 | 0.80 | PNMT (0.54) | PNMTCD44MAOBDRD2DRD3 | |
| SCHEMBL22225 | 0.77 | TSHR (0.46) | — | |
| SCHEMBL23306 | 0.77 | — | — | |
| SCHEMBL18584725 | 0.75 | HTR2C (0.52) | PNMTCD44MAOBDRD2DRD3 | |
| SCHEMBL5685195 | 0.74 | TSHR (0.43) | — | |
| SCHEMBL29193390 | 0.74 | TSHR (0.38) | — | |
| SCHEMBL467549 | 0.74 | TSHR (0.43) | — | |
| SCHEMBL233066 | 0.73 | PNMT (0.74) | PNMTCD44MAOBDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490367-B1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | claimed |
| US-7348339-B2 | 2-(4-amino-furazan-3-yl)-1-ethyl-N-[(2R)-2-morpholinylmethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide; Mitogen- and Stress-Activated Protein (MSK) and Rho (guanosine triphosphate) 1 or 2 kinase inhibitor; neurodegenerative diaeases; antiinflammatory, anticarcinogenic, antiviral and antibacterial agent | GLAXO GROUP LIMITED (GB) | 2008-03-25 | — | — | US | claimed |
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-09-08 | — | — | US | claimed |
| EP-1490367-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-29 | — | — | EP | claimed |
| WO-2003080610-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | claimed |
| US-7592357-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7547779-B2 | Preparation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-06-16 | — | — | US | disclosed |
| EP-1675552-A4 | PREPERATION OF 1,6-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2009-06-03 | — | — | EP | disclosed |
| EP-1718638-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20080234261-A1 | Preparation of 1,6-Disubstituted Azabenzimidazoles as Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-09-25 | — | — | US | disclosed |
| EP-1490367-B1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-7348339-B2 | 2-(4-amino-furazan-3-yl)-1-ethyl-N-[(2R)-2-morpholinylmethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide; Mitogen- and Stress-Activated Protein (MSK) and Rho (guanosine triphosphate) 1 or 2 kinase inhibitor; neurodegenerative diaeases; antiinflammatory, anticarcinogenic, antiviral and antibacterial agent | GLAXO GROUP LIMITED (GB) | 2008-03-25 | — | — | US | disclosed |
| EP-1675552-A2 | PREPERATION OF 1,6-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-07-05 | — | — | EP | disclosed |
| EP-1670466-A2 | PREPARATION OF 1, 6, 7- TRISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005082890-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-09-08 | — | — | US | disclosed |
| WO-2005037197-A2 | PREPERATION OF 1,6-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005034866-A2 | PREPARATION OF 1, 6, 7- TRISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-04-21 | — | — | WO | disclosed |
| EP-1490367-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003080610-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | NR4A3, XDH, MAPK8 | PNMT 3598/4885CD44 4799/4885MAOB 2854/4885 |
| US-20080234261-A1 | Preparation of 1,6-Disubstituted Azabenzimidazoles as Kinase Inhibitors | TNK2, ROCK1, ARHGDIB | PNMT 2895/4885CD44 4851/4885MAOB 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.